Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron (Nasdaq: GERN) granted stock options for an aggregate 202,500 common shares to five newly hired employees, effective July 17, 2026, as employment inducements.

Rhea-AI Summary

Geron (Nasdaq: GERN) granted stock options for an aggregate 202,500 common shares to five newly hired employees, effective July 17, 2026, as employment inducements. The options carry a ten-year term, a $1.44 exercise price matching the grant-date close, and four-year, service-based vesting.

News Explained

Geron granted options covering 202,500 common shares to five new employees, but the release does not report exercise; if additional shares are issued, existing holders’ percentage ownership would be reduced.

Argus Jul 23 session

+2.84% close to close Open Argus

Details

News Market Reaction – GERN

In the Jul 23 session, GERN gained 2.84%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Geron’s prior inducement-grant announcement was followed by a 2.9% 24-hour reaction, adding historic...

Analysis

Geron’s prior inducement-grant announcement was followed by a 2.9% 24-hour reaction, adding historical context to this hiring-related award; moderate short positioning remains a sourced volatility risk, while the vesting schedule merits monitoring.

Key Figures

Grant Date: July 17, 2026 Shares Under Option: 202,500 shares Recipients: Five employees +3 more

Grant Date

July 17, 2026

Effective date of inducement grants

Shares Under Option

202,500 shares

Aggregate grant to newly hired employees

Recipients

Five employees

Newly hired employees accepting employment

Exercise Price

$1.44 per share

Equal to the closing price on the grant date

Option Term

Ten years

Term of the stock options

Vesting Schedule

12.5% at six months; remaining shares over 42 months

Four-year vesting subject to continued employment

Historical Context

5 past events · Latest: Jul 14

5 events

1. Jul 14

   Inducement grant

   24h Move

   +2.9%

   Option grant covering 1,700,000 shares to newly appointed chief business officer

2. Jul 13

   Leadership appointment

   24h Move

   -5.3%

   Chinmaya Rath appointed chief business officer effective July 13, 2026

3. Jun 18

   Inducement grants

   24h Move

   +6.3%

   Options covering 690,000 shares granted to eight new employees

4. Jun 01

   Conference participation

   24h Move

   -3.2%

   Management scheduled for Goldman Sachs healthcare conference fireside chat

5. May 18

   Inducement grants

   24h Move

   -0.8%

   Options covering 333,750 shares granted to five new employees

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

exercise price, vesting, nasdaq listing rule 5635(c)(4)

3 terms

exercise price financial

"The stock options have an exercise price of $1.44 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"have a ten-year term and vest over four years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.

The stock options have an exercise price of $1.44 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.

The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO^® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

CONTACT:
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did Geron (GERN) grant on July 17, 2026?

Geron granted stock options for an aggregate 202,500 common shares to five new employees. According to Geron, these inducement awards were effective July 17, 2026, and were approved by the Board’s Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of the new Geron (GERN) inducement stock options?

The inducement stock options have an exercise price of $1.44 per share. According to Geron, this price equals the closing price of its common stock on the July 17, 2026 grant date, aligning the awards’ strike price with prevailing market value.

How do the Geron (GERN) inducement options granted in July 2026 vest?

The options vest over four years, subject to continued employment. According to Geron, 12.5% of each grant vests six months after employment begins, with the remaining shares vesting in equal monthly installments over the following 42 months.

How long is the term of Geron’s July 2026 inducement stock options (GERN)?

Each inducement stock option has a ten-year term from the grant date. According to Geron, employees may exercise vested options during this period, subject to the 2018 Inducement Award Plan and the applicable stock option agreement terms.

Under what plan were the July 2026 Geron (GERN) inducement stock options granted?

The options were granted under Geron’s 2018 Inducement Award Plan and its standard stock option agreement. According to Geron, the Compensation Committee approved these awards in line with Nasdaq Listing Rule 5635(c)(4) for inducement equity grants.

Why did Geron (GERN) use Nasdaq Listing Rule 5635(c)(4) for these stock option grants?

Geron used Nasdaq Listing Rule 5635(c)(4) to grant equity as an inducement for new hires. According to Geron, these options were material to the employees’ acceptance of employment and were approved by the Compensation Committee under that specific rule.